f-1

F-1 is IC50s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively. F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways.

Ginsenoside F1 (20(S)-Ginsenoside F1) is an enzymatically modified derivative of ginsenoside Rg1, showing competitive inhibition of the activity of CYP3A4 and a weaker inhibition of the activity of CYP2D6.

Kaji-ichigoside F1 shows antiinflammatory/antinociceptive action in acetic acid-induced writhing and hot plate testing and in a carrageenan-induced paw edema model in mice and rats. Kaji-ichigoside F1 exhibits in vivo hepatoprotective effects, it inhibite

Niga-ichigoside F1 is a natural product that activates Nrf2 and improves high-fat diet-induced hepatic steatosis in male mice, while also inhibiting the NF-κB pathway to alleviate DSS-induced ulcerative colitis.

Goshonoside F1 is a lipid metabolite of the semi-glutinous variety of rice and can be used as an indicator for breeding superior rice.

ATP synthase inhibitor 1 is an inhibitor of the c subunit of the F1/FO-ATP synthase complex. It inhibits mitochondrial permeability transition pore (mPTP) opening and does not affect ATP levels.

F1-RIBOTAC is a ribonuclease-targeting chimera (RIBOTAC) that reduces QSOX1-amRNA expression through an RNase L-dependent mechanism. It is applicable in cancer research. (Pink: RNA ligand; Black: linker; Blue: RNase L ligand.)

(3S)-GSK-F1 is a selective small molecule inhibitor of Type III Phosphatidylinositol 4‑Kinase Alpha (PI4KIIIα), pIC50=8.3.

Marstenacisside F1, a polyoxypregnanoside derivative of Tenacigenin B with anti-inflammatory properties, has been isolated from Marsdenia tenacissima. It suppresses lipopolysaccharide-induced nitric oxide (NO) production in RAW 264.7 cells.

F1, an anti-inflammatory peptide, incorporates the HIV-1 Tat protein transduction domain linked with a 15-amino acid sequence from residues 46-60 of the inhibitor of NF-κB kinase-interacting peptide (IKIP). It effectively blocks LPS-induced phosphorylation of IκB kinase α (IKKα) and IKKβ, along with the nuclear translocation of NF-κB (p65) in mouse peritoneal macrophages at 5 µM concentration. F1, administered at 5 mg/kg in vivo, significantly reduces IL-6, TNF-α, and IL-1β serum levels and enhances survival in a mouse sepsis model induced by LPS.

Ginsenoside F1 (Standard) is a reference standard for research and analysis in studies involving Ginsenoside F1. Ginsenoside F1 (20(S)-Ginsenoside F1) is an enzymatically modified derivative of ginsenoside Rg1, showing competitive inhibition of the activity of CYP3A4 and a weaker inhibition of the activity of CYP2D6.

Suavissimoside R1 is a natural product isolated from Rubus parvifolius, suitable for biochemical experiments and drug synthesis research.

DRF-1042, an orally active camptothecin analog, exhibits anticancer and insecticidal activities by inhibiting DNA topoisomerase I. It has been studied for its efficacy against solid tumors, including prostate and colon cancers.

DRF-1042 HCl is an orally active camptothecin analog with antitumor activity, inhibits DNA topoisomerase I, and is used in the study of refractory solid tumors.

BF-1 is a novel selective 5-HT2 receptor antagonist that acts by blocking neurogenic dural plasma protein extravasation induced by mCPP or BW723C86.BF-1 is used in the study of migraine.

CF-1743 is an anti-varicella zoster virus nucleoside and inhibits VZV replication. CF-1743 can be used in studies about infection of varicella and herpes zoster.

DF-1012 FA is a structural analog of DF-1012, a neuropeptide inhibitor used in the study of asthma and cough.

DF-1111301 is a novel anti-allergic compound with anti-histamine H1 and anti-PAF activity.

F-14512 (free base) is a topoisomerase II inhibitor for the study of acute myeloid leukemia.

PF-184298 is a serotonin and norepinephrine monoamine reuptake inhibitor (SNRI) that inhibits dopamine reuptake.

PF-17 can be used as a PUF60 inhibitor for the treatment of ovarian cancer.

PF-184563 is an effective and selective non-peptide antagonist of the V1a receptor with oral activity, suitable for studying Raynaud's disease and dysmenorrhoea.

F-17 is a promising virulence factor inhibitor, displaying substantial inhibitory effects on biofilm formation, elastase activity, pyocyanin production, and swarming motility. Additionally, F-17 exhibits a strong binding affinity towards LasR and PqsR. Notably, F-17 does not exhibit any discernible cytotoxicity [1].

F-14329, a tetramic acid fungal metabolite [1], is a chemical compound.